GT Biopharma Submits IND for B7-H3-Targeted NK Cell Therapy
Event summary
- GT Biopharma submitted an IND application for GTB-5550 TriKE, a B7-H3-targeted NK cell engager, in December 2025.
- The company aims to initiate a Phase 1 basket trial for GTB-5550 in 2026, targeting multiple solid tumor cancers.
- GT Biopharma reported a preliminary cash balance of approximately $7 million as of December 31, 2025, expected to extend into Q3 2026.
- GTB-5550 is designed for subcutaneous dosing, with a planned Phase 1 trial testing up to 7 dose levels.
The big picture
GT Biopharma's IND submission for GTB-5550 marks its entry into the solid tumor space, a significant shift from its current focus on myeloid blood cancers. The company is leveraging its proprietary TriKE® platform to target B7-H3, a marker expressed in a broad range of solid tumors. This move positions GT Biopharma to compete in a larger market segment, though success will depend on demonstrating clinical efficacy and managing its cash runway effectively.
What we're watching
- Clinical Progress
- How the Phase 1 data readout for GTB-3650 in 1H 2026 will impact the GTB-5550 program.
- Market Potential
- Whether GTB-5550 can capture a significant portion of the $362 billion global solid tumor market.
- Execution Risk
- The pace at which GT Biopharma can advance multiple clinical programs with limited cash runway.
Related topics